CHINA - 2023/02/15: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J) logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Johnson & Johnson (NYSE: JNJ) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company repor ...

On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion.Operational growth was 6.7%, and adjusted operational growth was 5.7%.Raymond James noted that the company’s initial 2025 EPS guidance was slightly better than anticipated, despite facing foreign exchange (FX) challenges. However, the MedTech ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a m ...

Nipocalimab Clinical Trial Results - Nipocalimab demonstrated a sustained reduction in autoantibody levels by up to 75% over 24 weeks in antibody-positive adult patients with generalized myasthenia gravis (gMG) [1] - The Phase 3 Vivacity-MG3 study met its primary endpoint, showing statistically significant and clinically meaningful improvement in MG-ADL scores over 24 weeks [1] - Nipocalimab had a tolerable safety profile, with adverse event discontinuation rates similar to placebo (5.1% vs 7.1%) [1] gMG Disease Overview - gMG is a chronic, rare, autoantibody-driven disease affecting an estimated 700,000 people worldwide [4] - The disease is characterized by fluctuating weakness of skeletal muscles, leading to symptoms like limb weakness, drooping eyelids, and difficulties with chewing, swallowing, speech and breathing [4] - Approximately 10-15% of new MG cases are diagnosed in adolescents, with over 65% of pediatric MG cases in the US diagnosed in girls [4] Nipocalimab Mechanism and Designations - Nipocalimab is an investigational monoclonal antibody designed to block FcRn and reduce levels of circulating IgG antibodies, including autoantibodies [6] - The therapy has received multiple FDA designations, including Fast Track for gMG in December 2021 and Breakthrough Therapy for Sjögren's disease in November 2024 [8] - Nipocalimab was granted Priority Review by the FDA in Q4 2024 for gMG treatment [8] Vivacity-MG3 Study Design - The Phase 3 study enrolled 199 gMG patients, with 153 being antibody-positive, in a 24-week double-blind placebo-controlled trial [5] - Patients received either nipocalimab plus standard of care (30 mg/kg IV loading dose followed by 15 mg/kg every two weeks) or placebo plus standard of care [5] - The primary endpoint was mean change in MG-ADL score from baseline over Weeks 22-24 in antibody-positive patients [5] Regulatory Submissions - Johnson & Johnson submitted a Biologics License Application to the FDA on August 29, 2024 and a Marketing Authorisation Application to the EMA on September 11, 2024 for nipocalimab in gMG [1] - The Priority Review designation by the FDA was supported by findings from the Phase 3 Vivacity-MG3 study [1]

Johnson & Johnson (JNJ -1.94%) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 years in a row. That qualifies it as a Dividend King, a company that has increased its dividend payment annually for at least 50 years. The company also has a higher-yielding payout. At around 3.4%, it's almost triple the S&P 500's (^GSPC 0.61%) dividend yield, which is near a more than 20-year low at 1.2%. The iconic healthcare company backs its high-yielding payout with a very healthy ...

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>Here are the key points:The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters. Total earnings for the 62 S&P 500 companies that have ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Johnson & Johnson (JNJ) announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with treatment-resistant depression (TRD).Spravato is presently approved in combination with an oral antidepressant to treat adults with TRD and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.Following the latest nod, Spravato became the first and only monotherapy fo ...

Financial Data and Key Metrics - The company will review its business results for the fourth quarter and full year 2024, along with the financial outlook for 2025 [3] Business Line Data and Key Metrics - No specific data provided in the content regarding individual business line performance or key metrics Market Data and Key Metrics - No specific data provided in the content regarding market performance or key metrics Company Strategy and Industry Competition - The presentation contains forward-looking statements regarding the company's future operating and financial performance, market position, and business strategy [4] Management Commentary on Operating Environment and Future Outlook - No specific commentary provided in the content regarding the operating environment or future outlook Other Important Information - Additional materials, including the presentation and associated schedules, are available on the Investor Relations section of the Johnson & Johnson website [3] Q&A Session Summary - No Q&A session details provided in the content

Johnson & Johnson’s (JNJ) fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings exclude intangible amortization expense and special items, including which, reported earnings were $1.41 per share, down 17.1% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Sales of this drug and medical devices giant came in at $22.52 billion, which marginally beat the ...